海南日报海口8月22日讯(海南日报全媒体记者 马珂)记者从省卫健委获悉，2025第八届海南国际健 康产业博览会(以下简称健博会)将于12月26日至29日在海南三亚保利国际博览中心举办。本届健博会 以"智领·健康新未来"为主题，将集中展示国际国内健康产业资源与科技创新成果，助力海南健康产业 高质量发展。 据介绍，本届健博会规划展览面积2万平方米、互动体验区域1万平方米。设有智慧医疗、创新药 械、高端康养和康复疗愈、特色中医、旅游与健康服务、保健美容等6大核心展区和1个特色活动区。同 时还将举办医疗人工智能与精准治疗发展论坛等10余场高端论坛。主办方将邀请超4000名专业买家、专 业观众、逾3万名社会观众参展参会。 本届健博会由海南省卫健委、省科技厅、农工党海南省委、省医保局、省药监局、博鳌乐城国际医 疗旅游先行区管理局、海南广播电视总台、海南日报社等8家单位主办。 本届健博会是国家批复允许政府机构参与主办的海南医疗健康领域唯一展会项目，也是海南自贸港 正式启动封关运作后的高端展览项目。 ...

Summary of Pulmonx (LUNG) FY Conference Call - August 12, 2025 Company Overview - **Company**: Pulmonx Corporation (LUNG) - **Industry**: Medical Technology, specifically focused on treatments for severe emphysema and COPD - **Market Size**: Total Addressable Market (TAM) is $12 billion, with $5 billion in the United States and $7 billion internationally [3][4] Core Points and Arguments - **Clinical Validation**: Pulmonx is recognized in the gold COPD guidelines as the standard of care for patients with severe emphysema, supported by four randomized controlled trials and over 150 published data pieces [5][6] - **Product Offering**: The Zephyr valves are a minimally invasive treatment option for emphysema, allowing trapped air to escape from hyperinflated lobes of the lungs, thus improving patients' breathing capacity [7][19] - **Patient Demographics**: There are approximately 3.8 million diagnosed emphysema patients in the U.S., with 1.5 million suffering from severe emphysema. Of these, 1.2 million have hyperinflation, and 500,000 are candidates for the Zephyr valve treatment [14][15] - **Revenue Model**: The average cost per procedure is estimated at $10,000, with an average selling price (ASP) of $2,500 per valve [15][16] Financial Performance - **Recent Growth**: The company reported a 22% revenue growth year-over-year, with Q2 revenue at $23.9 million, comprising $14.7 million from the U.S. and $9.1 million from outside the U.S. [33] - **Gross Margins**: Gross margins were reported at 72% for Q2, with guidance for the year set at 74% [34] - **Cash Position**: The company holds $84.2 million in cash, cash equivalents, and marketable securities [34] Strategic Initiatives - **Market Growth Strategy**: The company aims to grow through three main strategies: acquire, test, and treat. This includes direct-to-patient advertising, peer-to-peer education, and the introduction of the LungTrax Detect product to identify potential patients [20][22][25] - **Geographic Expansion**: Pulmonx is expanding into Japan and China, with ongoing studies and partnerships to enhance market presence [29] - **New Product Development**: The Aeroseal product is expected to launch in 2027, which will allow treatment for patients with collateral ventilation, potentially expanding the TAM significantly [30][31] Challenges and Delays - **U.S. Market Delays**: The company has faced delays in the implementation of initiatives, which has affected revenue guidance, now projected at $90 million to $92 million for the year, reflecting a growth of 7% to 10% [35] - **Patient Acquisition Cycle**: Patients identified through direct-to-patient advertising take longer to navigate the treatment funnel compared to those referred directly by pulmonologists [38][39] - **Operational Efficiency**: The company is implementing various operational efficiencies, including automation and zero-based budgeting, to manage costs amid changing revenue expectations [62][63] Additional Insights - **Sales Force Dynamics**: The U.S. sales force is experiencing some challenges, with a need for representatives who can engage deeply with the market rather than just opening accounts [57][58] - **Therapy Awareness Specialists**: The introduction of therapy awareness specialists has led to a 19% increase in patient identification in regions where they are deployed [49] This summary encapsulates the key points discussed during the Pulmonx FY Conference Call, highlighting the company's market position, financial performance, strategic initiatives, and challenges faced in the current business environment.

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Laekna, Inc. 來凱醫藥有限公司 風險提示 LAE103最終不一定能夠成功開發及商業化。本公司股東及潛在投資者於買賣本公 司證券時務請審慎行事。 自願公告 LAE103的新藥臨床試驗(IND) 已獲得美國食品藥品監督管理局(FDA)批准 本 公 告 由 來 凱 醫 藥 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）自 願 作 出，以告知本公司股東及潛在投資者本集團最新業務進展。 謹參照本公司於2025年6月30日就LAE103向美國食品藥品管理局（「美國FDA」）提 交新藥臨床試驗「( IND」)申請所發佈之公告。LAE103（ 一種針對Act RIIB的單克隆 抗體 ）為本公司自主研發、潛在用於治療肌少性肥胖症及其他肌肉相關疾病。 公司董事（「董事」）會（「董事會」）欣然宣佈，LA ...

Group 1 - The core viewpoint of the news is that Ruiyi Investment has conducted research on a listed company, Zhijiang Biology, focusing on its future development plans and ongoing projects in the field of molecular diagnostics and cancer screening [1] - Zhijiang Biology plans to invest approximately 60 million yuan in R&D for 2024, with expected growth in 2025, emphasizing innovation in tumor early screening, companion diagnostics, and precision treatment [1] - The company is collaborating with Sanyou Biology on four ongoing projects, with one project entering the invention patent application stage [1] Group 2 - Zhijiang Biology offers organoid services to research and medical institutions, providing customized models and one-stop solutions [1] - Future capital increases in Sanyou Biology will consider strategic layout, shareholder interests, and market conditions [1] - The company has completed three rounds of share purchases and is currently conducting the second purchase for 2025, with future plans depending on circumstances [1] Group 3 - The investment projects are focused on high technical barriers and strong core competitiveness, aiming to promote the transformation of innovative achievements [1] - The future development plan is driven by technological innovation, aiming to expand the product line and achieve a full industry chain layout while exploring international markets [1] - Overseas business plans include increasing global presence, establishing new smart manufacturing plants, and enhancing localized team building to improve customer management [1]

Core Insights - The conference aims to accelerate the transformation of medical research findings into practical treatments for patients, benefiting the general public [1][5] - The Guangdong-Hong Kong-Macao Greater Bay Area is highlighted for its unique advantages in enhancing collaboration and optimizing processes in clinical trials [2][3] Group 1: Conference Objectives and Structure - The conference, titled "International Clinical Trials Conference of the Guangdong-Hong Kong-Macao Greater Bay Area," focuses on improving the efficiency of clinical trials and the application of new therapies [1][3] - It emphasizes the importance of collaboration among regional medical resources to create a comprehensive innovation loop from basic research to technology breakthroughs and results transformation [3][4] Group 2: Expert Contributions and Discussions - Renowned experts, including editors from top medical journals and academicians, shared insights on clinical trial design and breakthroughs in gene therapy for rare diseases [2][4] - The conference featured discussions on optimizing treatment processes for critical conditions like cancer and cardiovascular emergencies, aiming to enhance patient outcomes [4][5] Group 3: Research and Development Focus - The conference underscored the need for research to be driven by clinical challenges, with a commitment to translating laboratory discoveries into effective clinical applications [4][5] - The Zhongshan Hospital, a key organizer, is recognized for its robust research capabilities and commitment to addressing major health issues through innovative solutions [5]

Investment Rating - The report does not explicitly provide an investment rating for the colorectal cancer drug industry Core Insights - Colorectal cancer is the third most common malignant tumor globally, with 2 million patients in 2023, including 537,000 in China, driving market growth due to rising incidence rates [4] - The domestic pharmaceutical industry is increasingly looking to expand internationally, with innovative drugs like furmonertinib setting benchmarks [4][18] - The market is expected to grow from 31.4 billion RMB in 2024 to 39 billion RMB by 2028, with a compound annual growth rate (CAGR) of 5.57% [8] Market Background - Colorectal cancer drug types are diverse, with treatment plans tailored to individual patient conditions [5] - The evolution of colorectal cancer drugs has seen significant advancements from the introduction of 5-FU in 1957 to the recent approval of innovative therapies [6] Market Status - The colorectal cancer drug market size increased from 22.3 billion RMB in 2019 to 29.7 billion RMB in 2023, with a CAGR of 7.43% [7][8] - The demand for treatment is urgent, with 83% of patients diagnosed at advanced stages and 44% experiencing metastasis [11] Market Competition - The competitive landscape includes a tiered structure with leading companies like Fuhong Hanlin and Meiji Pharma in the first tier, followed by others like Hengrui Medicine and Akeso [17][18] - The report highlights ten recommended brands, including Xiansheng Pharmaceutical and Weicheng Bio, which have made significant advancements in drug development [19][20][21] Development Trends - Precision therapy is becoming mainstream, with targeted and immune therapies establishing their roles in treatment [31] - Local innovative pharmaceutical companies are rapidly emerging, supported by global collaborations and comprehensive product lines [32] - Upgraded patient demands are driving innovations in service models, focusing on unmet clinical needs [33]

Investment Rating - The report suggests a positive outlook for the epilepsy drug industry, highlighting potential breakthroughs in new drug targets and a rich pipeline of anti-seizure medications (ASMs) under development [3][59]. Core Insights - Epilepsy is a common neurological disorder with a significant patient population, estimated at 51.7 million globally and approximately 9 million in China, with 500,000 to 600,000 active cases annually [3][59]. - The mechanisms of epilepsy are complex, leading to a substantial treatment gap, as about 30% of patients do not achieve effective seizure control with current therapies [3][59]. - The research and development pipeline for ASMs is active, focusing on precision medicine and multi-target mechanisms, with promising candidates like XEN1101, Bexicaserin, and Zorevunersen showing advanced clinical progress [3][59]. Summary by Sections Section 1: Epilepsy as a Common Neurological Disorder - Epilepsy affects a large number of individuals, with a global prevalence rate of 658 per 100,000 people and a 10.8% increase in prevalence from 1990 to 2021 [8]. - In China, the estimated prevalence is about 7.0 per 1,000, with 40,000 new cases each year, making it the second most common neurological condition after headaches [8][29]. Section 2: ASMs as the Current Treatment of Choice - ASMs are the primary treatment for epilepsy, but they have limited efficacy and significant side effects, which continue to impact patient outcomes [20][29]. - The market for epilepsy treatment is projected to grow from approximately $8.6 billion in 2024 to $13.9 billion by 2034, with a CAGR of 5.1% [24][29]. Section 3: Active R&D Pipeline for ASMs - The focus of ASM development is on precision treatment and individualized medication, with over 200 projects currently disclosed, many in advanced clinical stages [33][36]. - Notable candidates include XEN1101, a potassium channel opener, which has shown promising results in reducing seizure frequency in clinical trials [39][44]. Section 4: Valuation of Key Companies - The report includes a valuation table for key companies in the epilepsy drug market, highlighting their market capitalization and projected revenues [61]. - Companies such as Hainan Haiyao and Lizhu Group are noted for their active pipelines and potential for growth in the epilepsy treatment sector [61].

Investment Rating - The report maintains a "Positive" investment rating for the healthcare sector [11] Core Insights - Menin is identified as a crucial epigenetic regulatory factor that drives the abnormal activation of the HOX/MEIS1 axis in acute leukemia subtypes, making it an important target for precision therapy in AML [2][7] - As of June 2025, there are 9 Menin inhibitors in clinical development or already approved globally, with Revumenib showing a complete response rate (CRc) of 81% when combined with Azacitidine and Venetoclax, and a median overall survival (mOS) of 15.5 months [2][8] - Ziftomenib has demonstrated a CRc rate of 94% in newly diagnosed NPM1m patients when used in combination with the "7+3" regimen [9] Summary by Sections Menin Inhibitors Overview - Menin, encoded by the MEN1 gene, plays a key role in gene transcription regulation and maintaining genomic stability, particularly in AML where it drives leukemia stemness and disease persistence [7][20] - Menin inhibitors are particularly effective for AML subtypes that depend on KMT2A rearrangements and NPM1 mutations, which are associated with poor prognosis [27][29] Clinical Development of Menin Inhibitors - Revumenib, developed by Syndax Pharmaceuticals, is the first Menin inhibitor approved by the FDA, showing promising efficacy in clinical trials with a CRc rate of 43.9% and an overall response rate (ORR) of 63.2% [8][33] - Ziftomenib, developed by Kura Oncology, has received FDA fast track designation and has shown high efficacy in initial clinical trials, with CR rates of 88% for NPM1m patients [9][42] - BN104, developed by BioNova, has shown a CR/CRh rate of 60.9% in KMT2A-r patients and is positioned as a potential best-in-class Menin inhibitor [45] Market and Competitive Landscape - The report highlights the competitive landscape with multiple companies, including domestic firms, actively developing Menin inhibitors, indicating a robust pipeline and potential for market growth [31][45] - The acquisition of BN104 by Sihuan Pharmaceutical reflects strategic moves to strengthen global positioning in the Menin inhibitor market [45]

Pulmonx (LUNG) FY Conference June 11, 2025 10:00 AM ET Speaker0 Good morning, everyone. My name is Steve Williamson. I'm the President and CEO of Palmonix. Thanks for joining us today. I'll get started with a forward looking statement. If you're looking for more information on this and more detailed information, it can be found on the Investor section of our website under Investor Relations or our full 10 ks. Investment highlights. So here's pulmonics. This is what I'd like you to remember about pulmonics. ...

Summary of MBX Biosciences Conference Call Company Overview - **Company**: MBX Biosciences - **Industry**: Biotechnology - **Focus**: Development of peptide therapeutics for chronic hypoparathyroidism (HP) and post-bariatric hypoglycemia (PBH) [2][3] Key Points Upcoming Milestones - **Phase II Data Release**: Expected in Q3 2025 for AVAIL study, which is the first once-weekly PTH replacement therapy for chronic HP [2][6] - **Pipeline Development**: MBX has multiple clinical programs targeting significant unmet needs, including obesity [3][5] Product Candidates - **Lead Candidate**: Canvoparatide, a once-weekly PTH replacement therapy for chronic HP, with a U.S. prevalence of over 250,000 patients [5][6] - **Second Candidate**: MBX1416 for PBH, with an estimated U.S. prevalence of over 90,000 patients [7][8] - **Obesity Portfolio**: Includes NBX4291, a GLP-1 GIP co-agonist prodrug, with an IND filing expected in Q2 2025 [9][76] Clinical Trial Insights - **AVEIL Study Design**: 64 patients randomized to receive either canvoparatide or placebo, with a primary endpoint of treatment response defined as independence from active vitamin D while maintaining normal serum calcium levels [19][20] - **Expected Outcomes**: Aiming for a 55% responder rate in the treatment group compared to 7% in the placebo group, indicating a placebo-adjusted treatment response of approximately 48% [20][28] Safety and Efficacy - **Safety Monitoring**: Focus on hypo- and hypercalcemia excursions, with expectations of fewer excursions due to the drug's pharmacokinetic profile [51][52] - **Phase I Results**: Positive outcomes in healthy volunteers, with expected differences in response for HP patients due to their PTH deficiency [53][55] Competitive Landscape - **Comparison with Competitors**: Canvoparatide's 12-week results will be compared to Ascendis' Yorvy Pass, which showed a 64% response rate at 6 months [22][28] - **Differentiation Strategy**: Emphasis on the unique infusion-like pharmacokinetics and the potential for better tolerability in comparison to existing therapies [77][79] Financial Position - **Funding Status**: MBX is well-funded, with cash reserves to support operations until mid-2027, allowing for the advancement of multiple programs [4] Additional Insights - **Regulatory Pathway**: Plans to conduct an end-of-phase II meeting followed by a phase III trial based on the upcoming Phase II results [70] - **Market Potential**: The company believes its products have blockbuster revenue potential due to the significant unmet medical needs in the targeted conditions [5][6] This summary encapsulates the critical aspects of MBX Biosciences' conference call, highlighting the company's strategic direction, product pipeline, and anticipated clinical milestones.